Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H19NO3 |
Molecular Weight | 273.327 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CNC(=O)\C=C\C=C\C1=CC2=C(OCO2)C=C1
InChI
InChIKey=WHAAPCGHVWVUEX-GGWOSOGESA-N
InChI=1S/C16H19NO3/c1-12(2)10-17-16(18)6-4-3-5-13-7-8-14-15(9-13)20-11-19-14/h3-9,12H,10-11H2,1-2H3,(H,17,18)/b5-3+,6-4+
DescriptionSources: http://www.hmdb.ca/metabolites/HMDB30187Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25257731 | https://www.ncbi.nlm.nih.gov/pubmed/24848642 | https://www.ncbi.nlm.nih.gov/pubmed/20381363
Sources: http://www.hmdb.ca/metabolites/HMDB30187
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25257731 | https://www.ncbi.nlm.nih.gov/pubmed/24848642 | https://www.ncbi.nlm.nih.gov/pubmed/20381363
Perlonguminine is an alkaloid amide isolated from species of the genus Piper, a plant used in traditional medicine that demonstrates antifungal, anticancer, antihyperlipidemic, and anti-inflammatory properties. Perlonguminine selectively targets a wide spectrum of cancer cells and induce cancer cell death by initiating various pathways, such as apoptosis, necrosis, and autophagy. The elevation of reactive oxygen species (ROS), characteristic of oxidative stress, is an important mechanism by which Perlonguminine promotes cancer-selective cell death. However, the poor aqueous solubility of Perlonguminine is a serious concern for intensive investigations and clinical application.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20381363 |
6.31 nM [EC50] | ||
Target ID: WP1018 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28586745 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25257731
Rats wer2.4 mg/kg PE by intraperitoneal administration
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25257731
SH-SY5Y cells were cultured and maintained in Dulbecco's Modified Eagle Medium (DMEM) solutions (Gibco Laboratories, Grand Island, NY), supplemented with 10% fetal bovine serum (FBS, Gibco Laboratories, Grand Island, NY). Cellswere kept at 37 °C in a humidified 5% CO2/95% O2 incubator. The dissociated cells were seeded in poly-L-lysine-coated plates at a density of 5 × 105/cm2 and cultured in DMEM, supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 0.1 mg/ml streptomycin. The medium was changed twice weekly. After 8 days of culture, the SH-SY5Y cells were randomly divided into seven groups: normal group (no oxygen–glucose deprivation), oxygen–glucose deprivation group (control group) and oxygen–glucose deprivation +PE groups (2.5, 5, 10, 20 and 40 μM). For oxygen–glucose deprivation, the SH-SY5Y cellswere washed twice in glucose-free balanced salt solution (BSS), and incubated in BSS (no glucose) in a humidified chamber filled with 95% N2/5% CO2 for 3 h at 36.5 °C, while the normal group and PE 20 μM group (no oxygen–glucose deprivation) were filled with 5% CO2/95% O2 and incubated in glucose-free BSS. After oxygen–glucose deprivation, the cultureswere replaced into neurobasalmedium and incubated with PE (2.5, 5, 10, 20 and 40 μM) in a CO2 incubator for 12 h.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Piperlonguminine
Created by
admin on Sat Dec 16 01:52:52 GMT 2023 , Edited by admin on Sat Dec 16 01:52:52 GMT 2023
|
PRIMARY | |||
|
5950-12-9
Created by
admin on Sat Dec 16 01:52:52 GMT 2023 , Edited by admin on Sat Dec 16 01:52:52 GMT 2023
|
PRIMARY | |||
|
125178
Created by
admin on Sat Dec 16 01:52:52 GMT 2023 , Edited by admin on Sat Dec 16 01:52:52 GMT 2023
|
PRIMARY | |||
|
5320621
Created by
admin on Sat Dec 16 01:52:52 GMT 2023 , Edited by admin on Sat Dec 16 01:52:52 GMT 2023
|
PRIMARY | |||
|
DTXSID401021742
Created by
admin on Sat Dec 16 01:52:52 GMT 2023 , Edited by admin on Sat Dec 16 01:52:52 GMT 2023
|
PRIMARY | |||
|
HN39MC8KIO
Created by
admin on Sat Dec 16 01:52:52 GMT 2023 , Edited by admin on Sat Dec 16 01:52:52 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD